Abraxane 5 mg/ml powder for dispersion for infusion. clinical trials
12 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus–Pancreatic Cancer)
This study is testing different combinations of new drug treatments for people with advanced pancreatic cancer. Doctors want to see how well these combinations shrink tumours and if they are safe to use.
For: Pancreatic ductal adenocarcinoma (PDAC)Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
This study is looking at a new drug called Pralsetinib for advanced lung cancer where a specific genetic change (RET fusion) is present. It compares Pralsetinib to standard treatments to see if it works better or has fewer side effects for people who haven't had treatment for this type of cancer before.
For: RET fusion−positive · metastatic Non-Small Cell Lung CancerFrance · Netherlands · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
This study looks at a new drug, retifanlimab, alongside standard chemotherapy for advanced lung cancer. It aims to see if adding retifanlimab helps people live longer and if it's safe. It's for adults with specific types of non-small cell lung cancer that has spread.
For: Metastatic nonsquamous or squamous non-small cell lung cancerCzechia · Bulgaria - Ongoing, recruitingTherapeutic exploratory (Phase II)
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer
This study looks at a new way to scan for breast cancer using a special dye and a PET/CT scan. It compares this new scan with a standard test to see how well they match. The goal is to better understand and treat advanced triple-negative breast cancer.
For: Metastatic triple negative breast cancerSweden - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma
This study is testing a new medicine called SOT102 for stomach and pancreatic cancer. Researchers want to find the safest dose of SOT102, both alone and with standard treatments, and see if it helps shrink tumours. It's an early-stage study, open to adults.
For: gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinomaSpain · Czechia · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
This study looks at a new combination of treatments for advanced non-small cell lung cancer. It compares a new drug (MK-7684A) plus chemotherapy to an existing drug (pembrolizumab) plus chemotherapy, to see which works better and is safer.
For: Metastatic Non-Small Cell Lung CancerGermany · Spain · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study is testing a new way to treat early-stage lung cancer before surgery. It combines standard chemotherapy with a new drug called Tecentriq, or a dummy drug, to see if it helps patients live longer and stay cancer-free.
For: Early-Stage Resectable Non-small cell lung cancer (NSCLC)Spain · France · Slovenia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
This study is testing a new combination of treatments for advanced pancreatic cancer that hasn't been treated with chemotherapy before. It compares a new drug mix (irinotecan liposome, oxaliplatin, 5-fluorouracil/leucovorin) against a standard treatment (nab-paclitaxel, gemcitabine) to see which helps people live longer.
For: Metastatic Pancreatic AdenocarcinomaSpain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
This study is testing a new treatment, DF1001, for advanced or spreading cancers. It will look at how safe the treatment is, what side effects it causes, and how it affects the body. Researchers also want to see if it can help shrink tumours or stop them from growing.
For: Locally Advanced or Metastatic Solid Tumors · and Expansion in Selected IndicationsDenmark · Netherlands · Belgium - AuthorisedTherapeutic confirmatory (Phase III)
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
This study looks at different ways to give chemotherapy before surgery for pancreatic cancer. We want to see if a shorter or longer course of treatment works better in helping people live longer and preventing the cancer from growing.
For: pancreatic ductal adenocarcinomaItaly - Ongoing, recruitingPhase II and Phase III (Integrated)
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
This study is testing a new drug, SBP-101, alongside standard treatments (Nab-paclitaxel and Gemcitabine) for advanced pancreatic cancer that hasn't been treated before. Researchers want to see if adding SBP-101 helps people live longer.
For: Metastatic Pancreatic Ductal AdenocarcinomaItaly · Belgium · Germany - AuthorisedPhase II and Phase III (Integrated)
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
This study looks at new ways to treat advanced lung cancer using medicine and the body's own defense system. Researchers are testing if checking your blood for cancer DNA can help choose the best treatment to stop the cancer from growing.
For: metastatic NSCLC patientsItaly